분자 종양학 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Molecular Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1508473
리서치사:Transparency Market Research
발행일:2024년 05월
페이지 정보:영문 145 Pages
라이선스 & 가격 (부가세 별도)
한글목차
분자 종양학 시장 - 조사 범위
TMR의 조사 보고서 "세계의 분자 종양학 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지 세계 분자 종양학 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 분자 종양학 시장의 복합 연간 성장률(CAGR%)을 제공합니다.
이 보고서는 광범위한 1차 조사, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체와의 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조한 2차 조사, 그리고 분자 종양학 시장을 이해하기 위해 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 작성되었습니다.
시장 현황
2023년 시장 규모
23억 달러
2034년 시장 규모
74억 달러
CAGR
11%
이 보고서는 세계 분자 종양학 시장의 경쟁 환경을 조사했습니다. 세계 분자 종양학 시장에서 활동하는 주요 업체들이 확인되었으며, 각 업체는 다양한 속성별로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등은 세계 분자 종양학 시장의 기업들이 이 보고서에서 소개하는 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
개요
시장 역학
세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
주요 M&A
지역별/세계 규모 규제 시나리오
암 이환율
COVID-19의 영향 분석
제6장 세계 시장 분석과 예측 : 제품별
서론과 정의
주요 조사 결과/ 진전
시장 매출 예측 : 제품별, 2020-2034년
기기
시약
기타
제품별 시장의 매력
제7장 세계 시장 분석과 예측 : 용도별
서론과 정의
주요 조사 결과/ 진전
시장 매출 예측 : 용도별, 2020-2034년
폐암
유방암
대장암
난소암
췌장암
기타
용도별 시장의 매력
제8장 세계 시장 분석과 예측 : 기술별
서론과 정의
주요 조사 결과/ 진전
시장 매출 예측 : 기술별, 2020-2034년
PCR(rt-PCR, d-PCR)
NGS(차세대 시퀀싱)
마이크로어레이
FISH (Fluorescent in situ-hybridization)
기타
기술별 시장의 매력
제9장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과/ 진전
시장 매출 예측 : 최종사용자별, 2020-2034년
병원 및 진료소
진단 실험실
암센터 및 전문 클리닉
기타(정부 및 공중위생 기관)
최종사용자별 시장의 매력
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
국가/지역별 시장의 매력
제11장 북미 시장 분석과 예측
미국
캐나다
제12장 유럽 시장 분석과 예측
독일
영국
프랑스
스페인
이탈리아
기타 유럽
제13장 아시아태평양 시장 분석과 예측
중국
일본
인도
호주 및 뉴질랜드
기타 아시아태평양
제14장 라틴아메리카 시장 분석과 예측
브라질
멕시코
기타 라틴아메리카
제15장 중동 및 아프리카 시장 분석과 예측
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
제16장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
기업 개요
Thermo Fisher Scientific Inc.
Illumina, Inc.
Qiagen N.V.
Agilent Technologies, Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Roche Diagnostics
Genomic Health, Inc.
Myriad Genetics, Inc.
LSH
영문 목차
영문목차
Molecular Oncology Market - Scope of Report
TMR's report on the global molecular oncology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global molecular oncology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global molecular oncology market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the molecular oncology market.
Market Snapshot
Market Value in 2023
US$ 2.3 Bn
Market Value in 2034
US$ 7.4 Bn
CAGR
11%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global molecular oncology market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global molecular oncology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global molecular oncology market.
The report delves into the competitive landscape of the global molecular oncology market. Key players operating in the global molecular oncology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global molecular oncology market profiled in this report.
Key Questions Answered in Global molecular oncology Market Report:
What is the sales/revenue generated by molecular oncology across all regions during the forecast period?
What are the opportunities in the global molecular oncology market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Molecular Oncology Market - Research Objectives and Research Approach
The comprehensive report on the global molecular oncology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global molecular oncology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global molecular oncology market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Molecular Oncology Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Molecular Oncology Market Analysis and Forecasts, 2020-2034
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Regulatory Scenario by Region/Globally
5.3. Prevalence of Cancer
5.4. COVID-19 Impact Analysis
6. Global Molecular Oncology Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2020-2034
6.3.1. Instruments
6.3.2. Reagents
6.3.3. Others
6.4. Market Attractiveness By Product
7. Global Molecular Oncology Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2020-2034
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Colorectal Cancer
7.3.4. Ovarian Cancer
7.3.5. Pancreatic Cancer
7.3.6. Others
7.4. Market Attractiveness By Application
8. Global Molecular Oncology Market Analysis and Forecasts, By Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Technology, 2020-2034
8.3.1. PCR (rt-PCR, d-PCR)
8.3.2. NGS (Next Generation Sequencing)
8.3.3. Microarray
8.3.4. FISH (Fluorescent in situ-hybridization)
8.3.5. Others
8.4. Market Attractiveness By Technology
9. Global Molecular Oncology Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020-2034
9.3.1. Hospitals and Clinics
9.3.2. Diagnostic Laboratories
9.3.3. Cancer Centers and Specialty Clinics
9.3.4. Others (Government and Public Health Agencies)
9.4. Market Attractiveness By End-user
10. Global Molecular Oncology Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Molecular Oncology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product, 2020-2034
11.2.1. Instruments
11.2.2. Reagents
11.2.3. Others
11.3. Market Value Forecast By Application, 2020-2034
11.3.1. Lung Cancer
11.3.2. Breast Cancer
11.3.3. Colorectal Cancer
11.3.4. Ovarian Cancer
11.3.5. Pancreatic Cancer
11.3.6. Others
11.4. Market Value Forecast By Technology, 2020-2034
11.4.1. PCR (rt-PCR, d-PCR)
11.4.2. NGS (Next Generation Sequencing)
11.4.3. Microarray
11.4.4. FISH (Fluorescent in situ-hybridization)
11.4.5. Others
11.5. Market Value Forecast By End-user, 2020-2034
11.5.1. Hospitals and Clinics
11.5.2. Diagnostic Laboratories
11.5.3. Cancer Centers and Specialty Clinics
11.5.4. Others (Government and Public Health Agencies)
11.6. Market Value Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Application
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Molecular Oncology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product, 2020-2034
12.2.1. Instruments
12.2.2. Reagents
12.2.3. Others
12.3. Market Value Forecast By Application, 2020-2034
12.3.1. Lung Cancer
12.3.2. Breast Cancer
12.3.3. Colorectal Cancer
12.3.4. Ovarian Cancer
12.3.5. Pancreatic Cancer
12.3.6. Others
12.4. Market Value Forecast By Technology, 2020-2034
12.4.1. PCR (rt-PCR, d-PCR)
12.4.2. NGS (Next Generation Sequencing)
12.4.3. Microarray
12.4.4. FISH (Fluorescent in situ-hybridization)
12.4.5. Others
12.5. Market Value Forecast By End-user, 2020-2034
12.5.1. Hospitals and Clinics
12.5.2. Diagnostic Laboratories
12.5.3. Cancer Centers and Specialty Clinics
12.5.4. Others (Government and Public Health Agencies)
12.6. Market Value Forecast By Country, 2020-2034
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Application
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country
13. Asia Pacific Molecular Oncology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product, 2020-2034
13.2.1. Instruments
13.2.2. Reagents
13.2.3. Others
13.3. Market Value Forecast By Application, 2020-2034
13.3.1. Lung Cancer
13.3.2. Breast Cancer
13.3.3. Colorectal Cancer
13.3.4. Ovarian Cancer
13.3.5. Pancreatic Cancer
13.3.6. Others
13.4. Market Value Forecast By Technology, 2020-2034
13.4.1. PCR (rt-PCR, d-PCR)
13.4.2. NGS (Next Generation Sequencing)
13.4.3. Microarray
13.4.4. FISH (Fluorescent in situ-hybridization)
13.4.5. Others
13.5. Market Value Forecast By End-user, 2020-2034
13.5.1. Hospitals and Clinics
13.5.2. Diagnostic Laboratories
13.5.3. Cancer Centers and Specialty Clinics
13.5.4. Others (Government and Public Health Agencies)
13.6. Market Value Forecast By Country, 2020-2034
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Application
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country
14. Latin America Molecular Oncology Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product, 2020-2034
14.2.1. Instruments
14.2.2. Reagents
14.2.3. Others
14.3. Market Value Forecast By Application, 2020-2034
14.3.1. Lung Cancer
14.3.2. Breast Cancer
14.3.3. Colorectal Cancer
14.3.4. Ovarian Cancer
14.3.5. Pancreatic Cancer
14.3.6. Others
14.4. Market Value Forecast By Technology, 2020-2034
14.4.1. PCR (rt-PCR, d-PCR)
14.4.2. NGS (Next Generation Sequencing)
14.4.3. Microarray
14.4.4. FISH (Fluorescent in situ-hybridization)
14.4.5. Others
14.5. Market Value Forecast By End-user, 2020-2034
14.5.1. Hospitals and Clinics
14.5.2. Diagnostic Laboratories
14.5.3. Cancer Centers and Specialty Clinics
14.5.4. Others (Government and Public Health Agencies)
14.6. Market Value Forecast By Country, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Application
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country
15. Middle East & Africa Molecular Oncology Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Product, 2020-2034
15.2.1. Instruments
15.2.2. Reagents
15.2.3. Others
15.3. Market Value Forecast By Application, 2020-2034
15.3.1. Lung Cancer
15.3.2. Breast Cancer
15.3.3. Colorectal Cancer
15.3.4. Ovarian Cancer
15.3.5. Pancreatic Cancer
15.3.6. Others
15.4. Market Value Forecast By Technology, 2020-2034
15.4.1. PCR (rt-PCR, d-PCR)
15.4.2. NGS (Next Generation Sequencing)
15.4.3. Microarray
15.4.4. FISH (Fluorescent in situ-hybridization)
15.4.5. Others
15.5. Market Value Forecast By End-user, 2020-2034
15.5.1. Hospitals and Clinics
15.5.2. Diagnostic Laboratories
15.5.3. Cancer Centers and Specialty Clinics
15.5.4. Others (Government and Public Health Agencies)
15.6. Market Value Forecast By Country, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Application
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Company Profiles
16.2.1. Thermo Fisher Scientific Inc.
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Product Portfolio
16.2.1.3. Financial Overview
16.2.1.4. SWOT Analysis
16.2.1.5. Strategic Overview
16.2.2. Illumina, Inc.
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Product Portfolio
16.2.2.3. Financial Overview
16.2.2.4. SWOT Analysis
16.2.2.5. Strategic Overview
16.2.3. Qiagen N.V.
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Product Portfolio
16.2.3.3. Financial Overview
16.2.3.4. SWOT Analysis
16.2.3.5. Strategic Overview
16.2.4. Agilent Technologies, Inc.
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Product Portfolio
16.2.4.3. Financial Overview
16.2.4.4. SWOT Analysis
16.2.4.5. Strategic Overview
16.2.5. Abbott Laboratories
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Product Portfolio
16.2.5.3. Financial Overview
16.2.5.4. SWOT Analysis
16.2.5.5. Strategic Overview
16.2.6. Bio-Rad Laboratories, Inc.
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Product Portfolio
16.2.6.3. Financial Overview
16.2.6.4. SWOT Analysis
16.2.6.5. Strategic Overview
16.2.7. Roche Diagnostics
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Product Portfolio
16.2.7.3. Financial Overview
16.2.7.4. SWOT Analysis
16.2.7.5. Strategic Overview
16.2.8. Genomic Health, Inc.
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Product Portfolio
16.2.8.3. Financial Overview
16.2.8.4. SWOT Analysis
16.2.8.5. Strategic Overview
16.2.9. Myriad Genetics, Inc.
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
